{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:34Z","timestamp":1753891834680,"version":"3.41.2"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Treatment of hypopharyngeal carcinoma involves surgery, radiotherapy, and chemotherapy. The combination of docetaxel, cisplatin, and 5-fluorouracil as a standard induction chemotherapy regimen allows enhanced laryngeal preservation after surgery. In this study, our objective was to retrospectively analyze the short-term efficacy and adverse events of nab-paclitaxel plus cisplatin or nedaplatin plus tegafur\/gimeracil\/oteracil as an induction chemotherapy regimen for hypopharyngeal cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study involved 19 patients who received nab-paclitaxel plus cisplatin\/nedaplatin plus tegafur\/gimeracil\/oteracil every 21 days intervals for three cycles at the Affiliated Hospital of Guilin Medical University (December 2020 to February 2023). The primary endpoint was progression-free survival. Adverse events were assessed in all patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment response was evaluated after the second cycle. Clinical outcomes indicated that 2 (10.53%), 15 (78.94%), and 2 (10.53%) patients exhibited clinical complete response, partial response, and stable disease, respectively. The objective response and disease control rates were 89.47% (17\/19) and 100%, respectively. The pathological complete response rate was 71.43% (5\/7) among the seven patients who underwent surgery after three cycles. Following induction chemotherapy, 4 (21.05%), 2 (10.53%), and 2 (10.53%) patients received radiotherapy, chemotherapy, and chemotherapy plus immunotherapy, respectively, whereas 4 (21.05%) patients discontinued treatment. At the 17.43-month median follow-up, median progression-free survival was 17.6 months (95% confidence interval, 13.9-21.2). The most common grade 3 treatment-related adverse events were alopecia (36.8%), leukopenia (26.3%), and anemia (15.8%). No grade 4\/5 treatment-emergent adverse events were observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The combination of nab-paclitaxel, cisplatin\/nedaplatin, and tegafur\/gimeracil\/oteracil is a safe induction chemotherapy for treating hypopharyngeal cancer.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1504658","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:37:27Z","timestamp":1740379047000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin or nedaplatin plus tegafur\/gimeracil\/oteracil as induction chemotherapy regimen for hypopharyngeal cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Cailing","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyan","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieyin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenya","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangteng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mafei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds299","article-title":"Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors","author":"Braakhuis","year":"2012","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21022","article-title":"National Cancer Database report on cancer of the head and neck: 10-year update","volume":"31","author":"Cooper","year":"2009","journal-title":"Head Neck"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt223","article-title":"The molecular features of tongue epithelium treated with the carcinogen 4-nitroquinoline-1-oxide and alcohol as a model for HNSCC","volume":"34","author":"Osei-Sarfo","year":"2013","journal-title":"Carcinogenesis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0347(200007)22:4<380::AID-HED11>3.0.CO;2-E","article-title":"Cervical node metastases in laryngeal and hypopharyngeal cancer: a prospective analysis of prevalence and distribution","volume":"22","author":"Buckley","year":"2000","journal-title":"Head Neck"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0031","article-title":"Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Pfister","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6258-8","article-title":"Neoadjuvant chemotherapy for hypopharyngeal squamous cell carcinoma and personalized medicine in head and neck cancer","volume":"25","author":"Gordin","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.8.1592","article-title":"Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma","volume":"12","author":"Spaulding","year":"1994","journal-title":"Department Veterans Affairs Cooperative Laryngeal Cancer Study Group J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds065","article-title":"Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891","volume":"23","author":"Lefebvre","year":"2012","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"djv368","DOI":"10.1093\/jnci\/djv368","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, \u00b1 Docetaxel for larynx preservation","volume":"108","author":"Janoray","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01742-6","article-title":"Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil","volume":"25","author":"Shirasu","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24752","article-title":"Hypopharyngeal carcinoma: Do you know your guidelines","volume":"41","author":"Kwon","year":"2019","journal-title":"Head Neck"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hed.v38.S1","article-title":"Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma","author":"Kim","year":"2016","journal-title":"Head Neck"},{"key":"B20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40463-018-0310-y","article-title":"The role of induction chemotherapy followed by surgery in unresectable stage IVb laryngeal and hypopharyngeal cancers: a case series","volume":"47","author":"Sittitrai","year":"2018","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199609\/10)18:5<405::AID-HED3>3.0.CO;2-9","article-title":"Combined chemotherapy and radiotherapy versus surgery and postoperative radiotherapy for advanced hypopharyngeal cancer","volume":"18","author":"Zelefsky","year":"1996","journal-title":"Head Neck"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21613","article-title":"Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery","volume":"34","author":"Takes","year":"2012","journal-title":"Head Neck"},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4143\/crt.2014.340","article-title":"Definitive chemoradiotherapy versus surgery followed by adjuvant radiotherapy in resectable stage III\/IV hypopharyngeal cancer","volume":"48","author":"Kim","year":"2016","journal-title":"Cancer Res Treat"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.709234","article-title":"S-1 for the treatment of gastrointestinal cancer","volume":"13","author":"Satoh","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-199607000-00010","article-title":"Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators","volume":"7","author":"Shirasaka","year":"1996","journal-title":"Anticancer Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i41.15110","article-title":"S-1 in the treatment of pancreatic cancer","volume":"20","author":"Sudo","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s10120-015-0587-8","article-title":"The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis","volume":"19","author":"Ter Veer","year":"2016","journal-title":"Gastric Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J Control Release"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.027","article-title":"Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC","volume":"16","author":"Yoneshima","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-016-0614-4","article-title":"A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer","volume":"20","author":"Nakayama","year":"2017","journal-title":"Gastric Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02122-x","article-title":"First-line carboplatin\/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience","volume":"22","author":"Parisi","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14105","article-title":"Nab-paclitaxel monotherapy for relapsed small cell lung cancer: retrospective analysis and review","volume":"40","author":"Nakao","year":"2020","journal-title":"Anticancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1504658\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T06:37:30Z","timestamp":1740379050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1504658\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":33,"alternative-id":["10.3389\/fonc.2025.1504658"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1504658","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"article-number":"1504658"}}